ArticleIntensive care medicine experimental2026
The effect of dexmedetomidine on rocuronium-induced neuromuscular blockade and its reversal by sugammadex.
Article in Intensive care medicine experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDexmedetomidine (DEX) is increasingly used in the intensive care unit for sedation and also serves as an adjuvant in general anesthesia and in procedural sedations. We tested whether dexmedetomidine at different concentrations influences the activity of the neuromuscular junction at the diaphragm and whether DEX has an impact on the action of rocuronium at the diaphragm as well as the reversal of the neuromuscular block by sugammadex.
methods20 male Wistar rat phrenic nerve-hemidiaphragm system was used for our experiments. The concentration-response characteristics of DEX and rocuronium were quantified as the depression of the force amplitude of single twitches (ST) in response to electrical stimulation of the phrenic nerve. Rocuronium concentration-response curves were obtained with 0, 1, and 2.67 μg/ml DEX concentration. After a single dose of rocuronium, sugammadex doses were given until additional doses of sugammadex were not accompanied by a further increase in ST force amplitude. The concentration-response curve of sugammadex was also measured in the presence of 1 μg/ml DEX concentration.
resultsDEX at different doses negligibly reduces the force of the contractions and the contractility of the diaphragm. The EC50 of rocuronium [7.74 µM (6.99-8.57)] did not change significantly [7.18 µM (6.58-7.84); p = 0.27] with the addition of DEX 1 µg/ml. At 2.67 µg/ml DEX concentration, the ED50 of rocuronium was significantly reduced [6.37 µM (5.69-7.13); p = 0.015]. With 1 µg/ml DEX concentration, the EC50 of the sugammadex [2.04 µM (1.94-2.14)] needed for the reversal of rocuronium-induced neuromuscular blockade was significantly increased [2.45 µM (2.39-2.51); p < 0.01].
conclusionsDEX at clinically administered doses does not significantly influence the function of the neuromuscular junction at the diaphragm. Under routine dosing conditions, the action of the neuromuscular blocking agents and their reversal by sugammadex are also not modified by DEX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.